Avalo Therapeutics, Inc. (AVTX) has a consensus analyst rating of Buy, based on 5 analysts covering the stock. Of those, 3 recommend buying, 1 recommend holding, and 1 recommend selling.
The analyst consensus price target for AVTX is $44.50, representing a +220.1% upside from the current price of $13.9. Price targets range from a low of $39.00 to a high of $50.00.
